Italian guidelines show way out of screening muddle
This article was originally published in Clinica
The Italian Health Ministry has been urged to develop national screening programmes for the most common forms of cancer. A report just published by the Italian National Oncology Commission shows that current measures are at best disjointed and wasteful. It contains guidelines on measures for organising cancer prevention and care and has been published within the framework of Italy's 1994-1996 oncology programme (Gazzetta ufficiale, June 1st).
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.